

Ref. No: 1790
Date: 29th May 2025
Subject: Treatment of Breast Cancer

REQUEST AND RESPONSE

Answer the questions below in relation to the number of patients treated with specific medicines between the start of January 2025 to the end of March 2025, or the latest three-month period for which data is available. Please include data for all hospitals in the Trust.

Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of Jan 2025 and the end of Mar 2025, or latest 3-month period available?

Name of medicine	Number patients treated
1.1 Abemaciclib (Verzenios)	0
1.2 Alpelisib (Piqray)	0
1.3 Elacestrant (Orserdu)	0
1.4 Fulvestrant (fulvestrant or Faslodex)	0
1.5 Inavolisib (Inaqovi)	0
1.6 Palbociclib (Ibrance)	0
1.7 Ribociclib (Kisqali)	0
1.8 Capivasertib (Truqap)	0
1.9 Talazoparib (Talzenna)	0
1.10 Olaparib (Lynparza)	0

Q2. How many patients received the following medicines for early breast cancer in the 3 months between the start of Jan 2025 and the end of Mar 2025, or latest 3-month period for which data are available?

Name of combination or monotherapy	Number treated	patients
2.1 Abemaciclib (Verzenios)		
2.2 Ribociclib (Kisqali)		
2.3 Olaparib (Lynparza)		

Q3. How many patients received the following medicines with curative treatment intent in the 3 months between the start of Jan 2025 and the end of Mar 2025, or latest 3-month period for which data are available?

Name of combination or monotherapy	Number treated	patients
3.1 Abemaciclib (Verzenios)		
3.2 Ribociclib (Kisqali)		

Q4. How many patients were treated with the following medicines in combination with fulvestrant in the 3 months between the start of Jan 2025 and the end of Mar 2025, or latest 3-month period available?

Name of combination or monotherapy	Number treated	patients
4.1 Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex)		
4.2 Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex)		
4.3 Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex)		

Q5. How many patients were treated with Olaparib (Lynparza) for the following types of breast cancer in the 3 months between the start of Jan 2025 and the end of Mar 2025?

Type of breast cancer	Number treated	patients
5.1 All types of breast cancer		
5.2 Locally advanced or metastatic breast cancer		

Q6. How many patients were treated in total with the following products in the 3 months between 1st Jan 2025 to the end of Mar 2025, or latest 3-months for which data are available?

Name of medicine	Number patients treated
6.1 Pertuzumab (Perjeta)	
6.2 Pertuzumab with Trastuzumab (Phesgo)	
6.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab)	
6.4 Trastuzumab Deruxtecan (EnHertu)	
6.5 Trastuzumab Emtansine (Kadcyla)	
6.6 Tucatinib (Tukysa)	
6.7 Neratinib (Nerlynx)	

Q7. How many patients were treated with the following products for a diagnosis of Breast Cancer (*ICD-10 codes = C50*, D509*) in the 3 months between 1st Jan 2025 to the end of Mar 2025, or latest 3-months for which data are available?

Name of medicine	Number patients treated
7.1 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab)	
7.2 Trastuzumab Deruxtecan (EnHertu)	

Q8. How many patients received the following products with curative treatment intent in the 3 months between the start of Jan 2025 to the end of Mar 2025, or latest 3-month period for which data are available?


Treatment intent	Number patients treated
8.1 Pertuzumab (Perjeta)	
8.2 Pertuzumab with Trastuzumab (Phesgo)	
8.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, Trastuzumab)	
8.4 Trastuzumab Emtansine (Kadcyla)	

Q9. How many patients received the following products as part of neoadjuvant or adjuvant therapy in the 3 months between the start of Jan 2025 to the end of Mar 2025, or latest 3-month period for which data are available?

Treatment intent	Number patients treated
9.1 Pertuzumab (Perjeta)	
9.2 Pertuzumab with Trastuzumab (Phesgo)	
9.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab)	
9.4 Trastuzumab Emtansine (Kadcyla)	

Q10. How many patients received trastuzumab deruxtecan (Enhertu) for the following types of breast cancer in the 3 months between the start of Jan 2025 to the end of Mar 2025, or latest 3-month period for which data are available?

Treatment intent	Number patients treated
10.1 HER2+ ve Breast Cancer	
10.2 HER2- low Breast Cancer	

 Answer to Q2- 10

We have not used any of the drugs listed. Because of this the following questions would also be zero.